Forget the U.S. pharma/biotech bubble speculation and keep an eye on South Korea's Kosdaq, Reuters reports, adding that some firms are now trading at hundreds to tens of thousands of times earnings. Among the gainers is Kyung Nam Pharm, up 515%, or 278 times earnings per share, Reuters said. As well, iNtRON Biotechnology, up a mere 170% by comparison, trades at 27,603 times earnings per share. Report